News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Acasti Pharma Announces the Initiation of a Second Phase II Clinical Study and Consolidation of Its IP Position



12/5/2011 9:34:50 AM

LAVAL, Quebec, Dec. 5, 2011 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti) (TSX-V:APO), a subsidiary of Neptune Technologies & Bioressources Inc. (Neptune), announces the extension of its clinical development program by enrolling the first patients in its second phase II clinical trial designed to assess the safety, efficacy and dose response of its prescription drug candidate, CaPre®, for patients with hypertriglyceridemia.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES